Equipment Turns the Corner and FY25 Hits the High End; a Confirm-Not-Beat 2026 Guide Cools a Run-Up — Maintaining Outperform

Results vs. Consensus

Q4 2025 Scorecard

Full-Year 2025 Scorecard

Year-Over-Year Comparison (Q4)

Quarter-Over-Quarter Comparison

Quality of Beat

Revenue: Core growth of +2.5% decelerated modestly from Q3's +3.0% but kept the full year at +2%. The deceleration is partly the respiratory pull-forward dynamic reversing (Q3 had pulled some demand forward) and a tougher Discovery & Medical comp. The composition stayed broad: Biotechnology +6% core, Diagnostics +2%, Life Sciences +0.5% (positive, the first non-negative print of the year). Geographically, developed markets were up low-single (North America ~flat, Western Europe mid-single) and high-growth markets up mid-single despite a low-single China decline.

Margins: The 130bp year-over-year decline in adjusted operating margin (to 28.3%) is the headline negative, and it is deliberate. Management front-loaded expensed productivity investments — rooftop consolidation, process efficiency, headcount — into Q4 to clean the 2026 base and fund >100bp of 2026 margin expansion. Danaher does not one-time these out, so the in-year optics suffer while peers' adjusted margins would not. The full-year margin of 28.2% held roughly flat despite the spend, which is the more telling number.

EPS: The $2.23 (+4.0%) beat the $2.14 consensus, with the FY landing at the $7.80 high end. As in prior quarters, the Street had modeled roughly flat (consensus $2.14 was essentially the Q4 2024 level), and Danaher grew. The deceleration in EPS growth (from +10% in Q3 to +4% in Q4) reflects the margin investment and the absence of a respiratory pull-forward tailwind, not a demand problem. Share count continued to drift lower on buyback.

Segment Performance

Biotechnology — +6% Core, and the Equipment Turn We Were Waiting For

Biotechnology core grew 6%, but the news was beneath the headline: bioprocessing equipment returned to growth at a mid-single-digit rate, the first positive equipment quarter this cycle, on a third consecutive quarter of sequential order growth. Consumables stayed high-single-digit on robust commercialized-therapy (monoclonal antibody) demand. Discovery & Medical declined low-single-digits on a tough medical-filtration comp and continued protein-research-instrument weakness tied to academic funding.

Management characterized the equipment momentum as concentrated in shorter-cycle line additions and brownfield expansions, with US reshoring-related greenfield investments expected to provide incremental upside over time. For 2026, bioprocessing is guided high-single-digit (consumables at the upper end of high-single, equipment assumed flat off the mid-teens 2025 decline) — a deliberately conservative equipment assumption given the order trajectory.

"We were also encouraged by the return to equipment revenue growth in the quarter and by the third consecutive quarter of sequential equipment order growth… current momentum in our equipment order book and funnels is concentrated around shorter-cycle projects such as line additions and brownfield expansions, with U.S. reshoring-related greenfield investments expected to provide incremental upside over time." — Rainer Blair, President & CEO

Assessment: This is the milestone of the quarter. At initiation we said the equipment leg was the difference between a high-single-digit and a double-digit bioprocessing recovery, and that its conversion was the key upside. It has now converted — revenue growth plus three straight quarters of sequential order growth. Management is rightly cautious ("one quarter does not make a trend") and guides equipment flat for 2026, which means the order momentum is pure upside to the bioprocessing line and to the 2026 core range.

Life Sciences — +0.5% Core, Back in Positive Territory

Life Sciences turned positive (+0.5% core) for the first time in 2025, with instruments roughly flat (SCIEX up mid-single on the ZenoTOF 8600 and a third straight quarter of pharma end-market growth) and a modest European budget flush late in the quarter. Consumables still declined on the two-large-customer plasmid/mRNA headwind, but Abcam delivered a third consecutive month of growth on recombinant proteins and pharma initiatives, with operating margins now 500bp above the acquisition level. Academic and government stayed muted but stable.

"We were encouraged to see another quarter of sequential improvement at Abcam as key commercial initiatives in pharma and recombinant proteins delivered solid growth, partially offsetting ongoing softness in academic research." — Rainer Blair, President & CEO

Assessment: The show-me segment finally printed positive. The trajectory (instruments inflecting, pharma growing three quarters running, Abcam recovering, the two-customer comp lapping) supports the 2026 plan for modest improvement, even though management conservatively guides Life Sciences roughly flat. Academic/government remains the muted overhang and the swing factor for upside. This is no longer a drag on the company; it is a small positive contributor.

Diagnostics — +2% Core, Two Franchises Near Double-Digits Ex-China

Diagnostics grew 2% core. Clinical diagnostics grew mid-single-digits (high-single ex-China), with Leica Biosystems and Radiometer each up nearly 10% on broad instrument-and-consumable strength, and Beckman Coulter Diagnostics up mid-single globally (high-single in immunoassay) — its sixth consecutive quarter of mid-single-digit-or-better core growth ex-China. Cepheid respiratory of ~$500M exceeded expectations on an active season (high circulating-virus prevalence), and non-respiratory grew low-double-digits (sexual health ~+30%, hospital-acquired-infection assays mid-teens). Cepheid received FDA clearance for its multiplex GI panel.

"This is Beckman's sixth consecutive quarter of mid-single-digit or better core growth outside of China and caps off a year of sustained momentum across its innovation and commercial engines." — Rainer Blair, President & CEO

Assessment: Ex-China, Diagnostics is a healthy mid-single-digit-plus grower with three standout franchises (Leica/Radiometer near double-digits, Beckman's six-quarter streak, Cepheid's non-respiratory double-digits). The China VBP drag is moderating into 2026 (~$75–100M), and the raised respiratory endemic (~$1.8B) reflects genuine seasonal demand. Diagnostics is set up to accelerate to mid-single-digit in 2026 as China laps — one of the clearest sources of the 2026 core acceleration.

Key Topics & Management Commentary

Overall Management Tone: Confident and forward-leaning on the recovery, while keeping the guide conservative by design. Management led with the equipment inflection and the constructive 2026 setup, leaned harder into the M&A readiness than in prior quarters, and framed reshoring as "early innings of a long-term investment cycle." The conservatism was deliberate and located in the right places — equipment assumed flat, core anchored to the low end, China taken cautiously — which is why the in-line guide read as a floor rather than a ceiling.

1. Bioprocessing Equipment Returns to Growth

The strategic milestone of the quarter. Bioprocessing equipment grew mid-single-digits in Q4 after a mid-teens 2025 decline, on a third consecutive quarter of sequential order growth. Lead times on consumables have shortened (so a book-to-bill around one is "exactly where it needs to be"), and equipment momentum is concentrated in shorter-cycle line additions and brownfield expansions. Management was careful not to over-claim — "one quarter, a trend does not make" — and guides equipment flat for 2026.

"We have talked about equipment orders increasing sequentially here the last three quarters in a row. Then, of course, we grew revenue in the fourth quarter, so we feel comfortable that we are starting to head in the right direction… but one quarter of growth, we are not ready to call that a trend yet." — Rainer Blair, President & CEO

Assessment: The equipment leg inflecting is the most thesis-relevant development since we initiated. It validates the bioprocessing-recovery pillar in full (consumables compounding plus equipment turning) and, because 2026 guidance assumes equipment flat, any continuation of the order momentum is upside to both the bioprocessing line and the 3–6% core range. The conservative posture is the right one after a multi-year equipment downturn, but the directional signal is unambiguous.

2. The 2026 Guide: $8.35–$8.50, High-Single-Digit EPS Growth

Management initiated 2026 adjusted EPS guidance of $8.35–$8.50 (+7–9% off the $7.80 base) on 3–6% core revenue growth, confirming the high-single-digit framework from October. The CFO laid out the bridge: low-end core (3–4%), 35–40% fall-through, a $0.30 benefit from the 2025 cost actions ($250M net savings), and below-the-line/FX netting to roughly zero, producing >100bp of adjusted operating margin expansion.

"We are assuming the low end of the core growth… 35% to 40% fall-through. We have got a 30¢ benefit from the 2025 cost actions… If you do that math, you get $8.35 to $8.50. If we do better from a core growth perspective… there's probably likely some upside here to EPS." — Matt McGrew, CFO

Assessment: The guide confirms rather than beats — the Street already sat near $8.40–$8.50 after October, which is the proximate reason for the stock's reaction. But the construction is conservative and the algorithm is sound: high-single-digit EPS growth off a low-end-core assumption, with explicit upside if core accelerates, and capital deployment excluded entirely. We treat $8.42 as a conservative anchor and see the realistic 2026 number drifting higher as the year progresses (the pattern in 2025).

3. Respiratory Endemic Raised to ~$1.8B

For the first time in years, management raised the Cepheid respiratory endemic assumption — to ~$1.8B for 2026 from the $1.7B it had held since 2021 — after revisiting seasonal trends. The Q4 respiratory print of ~$500M exceeded expectations on high circulating-virus prevalence, and Q1 2026 is expected at ~$500M.

"Over the past several weeks, we have worked closely with the team to better understand seasonal trends and revisit our assumption for respiratory revenue in a typical year. As a result, we expect respiratory revenue of approximately $1.8 billion for the full year 2026." — Rainer Blair, President & CEO

Assessment: A quietly meaningful positive. We had flagged the repeatedly-conservative $1.7B as a likely source of held-back upside; management has now reset the base ~$100M higher, which flows directly to the 2026 Diagnostics line and supports the segment's acceleration. It is also a tell that the prior conservatism was real — and that management raises only when the data forces it, which lends credibility to the rest of the conservative 2026 build.

4. Productivity Investments and the Margin Trajectory

Q4 adjusted operating margin fell 130bp year-over-year as expensed productivity investments (rooftop consolidation, process efficiency, headcount reduction) more than offset volume leverage. These are traditional DBS actions that Danaher does not one-time out; ~$250M of net 2026 savings (~$0.30 of EPS) results, supporting >100bp of 2026 margin expansion. The Q1 2026 adjusted operating margin is guided ~28.5%, with the cost benefit concentrated in the second half.

"This is traditional Danaher Business System-type productivity improvement, where we are certainly consolidating rooftops but also driving process efficiency… we expect the cost savings that we have generated there to sustain here for the long term." — Rainer Blair, President & CEO

Assessment: The 130bp Q4 margin decline is an investment, not a deterioration. Because Danaher expenses rather than excludes these costs, the 2026 base is genuinely clean and the >100bp expansion is incremental and partly de-risked by realized savings. The decision to front-load the spend into a seasonally strong quarter (absorbing it where volume leverage cushions the optics) is disciplined capital stewardship.

5. Capital Allocation: M&A Environment "More Constructive"

With net leverage below 2x debt/EBITDA and ~$5.3B of annual FCF, management struck the most M&A-ready tone of our coverage window: valuations are "moving in the right direction," interest rates have moderated, cultivation remains "as strong as ever," and the balance sheet is "prime" to act on something potentially more sizable. The framework is unchanged — attractive end markets with long-term tailwinds, defensible assets, and a model that works on ROIC.

"The M&A environment is more constructive. We have seen some valuations moving in the right direction. Interest rates have moderated a little bit, and our cultivation and our bias towards M&A remain as strong as ever… the balance sheet is prime." — Rainer Blair, President & CEO

Assessment: The clearest signal yet that capital deployment is moving from optionality toward action. The 2026 EPS guide explicitly excludes capital allocation, so a sizable accretive deal would be additive to the +7–9% organic algorithm. Danaher's DBS-driven M&A playbook is its historical compounding engine; a "more constructive" environment plus a primed balance sheet is the setup for the next leg of the long-term story.

6. Reshoring: "Early Innings of a Long-Term Investment Cycle"

Management framed reshoring/regionalization as a structural, multi-year equipment driver. Equipment investment has been muted for years while underlying demand stayed strong, implying catch-up is required just to meet existing demand; layering reshoring on top points to an extended capital cycle. The path runs brownfield-first (faster, using existing facilities) before greenfield (multi-year planning and execution), with timing hard to pinpoint.

"We really believe we could be in the early innings of a long-term investment cycle. As you know, we are really quite well-positioned to support those investments going forward." — Rainer Blair, President & CEO

Assessment: The longest-dated and largest unmodeled upside in the thesis. The combination of (1) deferred equipment demand from years of under-investment against rising volumes, and (2) reshoring/regionalization adding incremental capacity needs, points to a potential multi-year bioprocessing equipment up-cycle. None of it is in the 2026 guide (equipment assumed flat), making any conversion incremental to the +7–9% EPS algorithm.

7. China: Bioprocessing Growing, Diagnostics VBP Moderating

China was a low-single-digit decline overall, but the composition kept improving. Bioprocessing in China is expected to grow in 2026 (biotech monetization via licensing/IPOs is firming demand), and the diagnostics VBP headwind is moderating as Danaher laps the late-2024 reimbursement changes (2026 drag ~$75–100M). Danaher localized most of its China diagnostics manufacturing by year-end, positioning it advantageously against the 20% local-manufacturing pricing benefit.

"Our fourth-quarter bioprocessing business in China is coming off of a large comp, but the underlying activity level continues to strengthen… we expect China bioprocessing to grow in 2026." — Rainer Blair, President & CEO

Assessment: China continues its shift from headwind toward neutral-to-positive. The diagnostics VBP drag is shrinking and quantified, bioprocessing is set to grow, and localization is a relative advantage. This de-risks one of our initiation bear pillars further and is a contributor to the 2026 Diagnostics acceleration.

8. The Path Back to the Long-Range High-Single-Digit Framework

Asked about the path back to the long-range plan, management declined to commit to 2027+ but reaffirmed the structural framework: the growth drivers (biologics proliferation, life-science research advancement, diagnostics moving closer to the patient) are intact, and as end markets recover, Danaher returns to high-single-digit core growth over time. 2026's 3–6% is framed as a step on that recovery path.

"We do not see any change to our long-term framework. As these end markets continue to recover, we will get back to that high-single-digit growth over time." — Rainer Blair, President & CEO

Assessment: The framing matters for the multiple. If 2026's 3–6% is a waypoint back toward high-single-digit core (with margin expansion and capital deployment on top), the through-cycle earnings algorithm is low-double-digit EPS growth — which supports the historical 25–30x multiple. The risk is that "over time" stretches if academic/government and equipment recoveries lag; the opportunity is that a faster recovery pulls the re-rating forward.

Guidance & Outlook

The 2026 guide is conservative by construction. Management built the $8.35–$8.50 EPS off the low end of the 3–6% core range (3–4%), 35–40% fall-through, the $0.30 cost-action benefit, and FX/below-the-line netting to zero — with explicit upside if core accelerates. By segment, 2026 assumes bioprocessing high-single-digit (equipment flat), Life Sciences/D&M roughly flat, and Diagnostics low-single-digit (mid-single ex-respiratory/China as VBP moderates).

The shape of the year: like 2025, 2026 is back-half-weighted. Q1 core is guided low-single-digit and builds through the year on easing Life Sciences consumables comps, modest end-market improvement, and easier China/respiratory comps; EPS follows, with the second half the biggest beneficiary of the 2025 cost actions.

Street at: Consensus 2026 EPS sat near the low-$8.40s entering the print, so the guide was roughly in line — the proximate reason for the −4.8% reaction. The upside levers (equipment momentum continuing, Life Sciences recovering faster, China accelerating, and any capital deployment) are all excluded from the guide.

Guidance style: Classic Danaher conservatism with a recovery overlay. Equipment assumed flat despite returning to growth; core anchored to the low end; capital deployment excluded; the only place management raised an assumption (respiratory) was where the data clearly forced it. Each conservative choice is a potential source of upside rather than risk.

Analyst Q&A Highlights

What Gets Danaher From 3% to 6% Core in 2026

The opening question pressed on how much conservatism is embedded in the 3–6% range and what drives the high end. Management level-set on the segment build (which lands near 3%) and named the two largest upside levers: a broader Life Sciences end-market recovery and bioprocessing exceeding high-single-digit.

Q: "You're opening with a 3% to 6% core revenue guide… if you do the sum of the parts, it gets you closer to that 3%… how much conservatism is embedded in that, or what are the levers… getting you closer to that six?"
— Michael Ryskin, Bank of America

A: "There's probably two larger drivers… One is to see continued improvement across our life science end markets… we would like to see that improved biotech funding environment fall through now to an increasing order book. The other lever is bioprocessing, where seeing better-than-high-single-digit growth for the year with equipment potentially accelerating or even consumables accelerating more as we see more biosimilars and mAb production increasing."
— Rainer Blair, President & CEO

Assessment: The guide build skews to the low end (~3%), so the +7–9% EPS algorithm rests on a conservative top line. The two named upside levers — a Life Sciences recovery and bioprocessing exceeding high-single-digit (equipment accelerating) — are precisely the dynamics that inflected in Q4. If either continues, the realistic 2026 core lands in the upper half of the range and EPS drifts above the guide, the same pattern we saw play out through 2025.

The Bioprocessing Order Book Behind the 2026 Outlook

A follow-up probed the Q4 order book and book-to-bill for both consumables and equipment, and the confidence behind the 2026 bioprocessing outlook given easy equipment comps but tougher consumables comps.

Q: "Can you talk a little bit about the order book, maybe book-to-bill, how that shaped up in the fourth quarter for consumables and for equipment… what the orders look like exiting the year and how that supports next year's outlook?"
— Michael Ryskin, Bank of America

A: "The order book fully supports the high-single-digit growth… the lead times have gotten much shorter on the consumable side, so having a book-to-bill there of around one is exactly where it needs to be… We have talked about equipment orders increasing sequentially the last three quarters in a row… one quarter of growth, we are not ready to call that a trend yet, but the orders… are encouraging."
— Rainer Blair, President & CEO

Assessment: The reframing of book-to-bill is important — with shorter consumables lead times, "around one" is now the healthy steady-state rather than a warning sign (it had read as a soft spot at initiation). On equipment, three straight quarters of sequential order growth plus a revenue inflection is a genuine turn, conservatively guided flat. The 2026 bioprocessing outlook is well-supported on consumables and carries equipment upside.

Why Equipment Wasn't Guided Higher Despite the Q4 Growth

Given the Q4 equipment growth and favorable 2026 comps, an analyst asked why management did not guide equipment higher, and whether there had been Q4 pull-forward. The CFO attributed it to prudence after a multi-year downturn.

Q: "Given the strength of equipment growth in the fourth quarter and favorable comparisons… it's a smidge surprising you didn't guide for maybe a little more growth at that line. Was there any pull-forward of demand into Q4? Or is this just maybe some extra prudence?"
— Douglas Schenkel, Wolfe Research

A: "Not too dissimilar to what we saw on the consumable side maybe six or eight quarters ago. It's encouraging to see… mid-single-digit growth out of the equipment, but it's just one quarter… until we have a few more data points… we are just going to go ahead and guide the flat. I think it's a good place to start. Let's see how the year progresses."
— Matt McGrew, CFO

Assessment: The "six or eight quarters ago" analogy to the consumables recovery is the tell — management is treating the equipment turn the way it treated the consumables turn, conservatively at first and then raising as the data confirms. Guiding equipment flat off a returning-to-growth base builds in a margin of safety and sets up beat-and-raise potential through 2026. This is the conservatism that makes the in-line guide a floor.

Margin Bridge to >100bp of 2026 Expansion

An analyst asked for the puts and takes behind the >100bp of 2026 margin expansion. The CFO walked the full EPS bridge, anchoring the construction to the low end of core.

Q: "I wanted to push a little bit more on the margin puts and takes for 2026. You talked about the $250 million cost actions… biotechnology, your highest-margin segment, growing the fastest… Is there anything else that stands out? I'm just trying to think about the 100bps."
— Jack Meehan, Nephron Research

A: "We are assuming the low end of the core growth… 3% to 4%. Assuming 35% to 40% fall-through. We have got a 30¢ benefit from the 2025 cost actions… that's in that 100 basis points of margin expansion… below-the-line stuff in FX… I just assume all that nets to zero. If you do that math, you get $8.35 to $8.50. If we do better from a core growth perspective… there's probably likely some upside."
— Matt McGrew, CFO

Assessment: The cleanest possible articulation of the 2026 algorithm. The >100bp expansion is built on low-end core plus a de-risked $0.30 cost benefit, with FX netted out — so the margin and EPS guides carry the same conservatism as the top line. Mix (Biotechnology, the highest-margin segment, growing fastest) is an additional unquantified tailwind. The math says $8.42 midpoint is a floor, not a stretch.

M&A Readiness for Something More Sizable

With the balance sheet liquid (leverage below 2x) and the business stabilizing, an analyst asked whether Danaher is in a better position to move on something larger and more aggressive. Management described a "more constructive" environment and a primed balance sheet.

Q: "Can you just describe the M&A environment and your readiness and priorities to potentially get a little more aggressive… whether you feel you're in a better spot now… to move on something potentially more sizable?"
— Douglas Schenkel, Wolfe Research

A: "The M&A environment is more constructive. We have seen some valuations moving in the right direction. Interest rates have moderated… our cultivation and our bias towards M&A remain as strong as ever… the balance sheet is prime… We like the setup."
— Rainer Blair, President & CEO

Assessment: The most forward capital-deployment commentary in our coverage window. "More constructive" valuations plus a primed balance sheet and unchanged ROIC discipline is the setup for a sizable accretive deal — the historical Danaher compounding lever. Excluded from the 2026 guide, it is a clean upside catalyst to the rating, and the most likely source of a step-change in the EPS algorithm.

Life Sciences: Real Recovery or an Elevated Q4 Base?

An analyst asked whether Q4 Life Sciences strength (a European budget flush) is a clean jumping-off point for 2026 or an elevated base, and what is needed to push Life Sciences from flat to a few percent growth.

Q: "Is it possible there were some push-outs from earlier in the year that might have come in around year-end? What can you build off of in April versus what might be an elevated base?"
— Jack Meehan, Nephron Research

A: "There was probably a little bit of a budget flush. We saw that especially in Europe. Not enormous… The upside we are looking for in life sciences comes out of two categories. One being academic and government — we need more stabilization… Then we would like to see biotech take advantage of the improved funding environment… start seeing that fall through into the order book."
— Rainer Blair, President & CEO

Assessment: Management is appropriately measured — acknowledging a modest European budget flush (so Q4 is a slightly elevated base) while guiding Life Sciences roughly flat for 2026. The two upside conditions (academic/government stabilization, biotech funding converting to orders) are exactly the macro variables outside Danaher's control. Flat-guided Life Sciences is conservative; a genuine instrument-cycle recovery is the largest swing factor to the high end of the 3–6% range.

What They're NOT Saying

1. A 2027+ path to the long-range plan: Management reaffirmed the structural high-single-digit framework "over time" but declined to commit to when Danaher returns to it. With 2026 guided to 3–6%, the timing of the full recovery — and thus the timing of any multiple re-rating — is left open.
2. Whether the equipment turn is durable: Three straight quarters of sequential order growth and a revenue inflection, but management explicitly would not "call a trend" and guided equipment flat. The durability of the most important inflection of the quarter is deliberately left unconfirmed.
3. M&A specifics: A "more constructive" environment and readiness for something "more sizable," but no target, sector, or size. The largest potential swing factor to the multi-year algorithm remains unquantified.
4. Per-segment margins: Company-level adjusted operating margin (28.3%) was given, with all three segments noted as down, but no segment-level margin detail — obscuring how unevenly the productivity investments and mix are landing.
5. The cost-action runway beyond 2025: The $175M/$250M-net program is characterized as one-time and not repeating in 2026. Management did not address whether a further structural program could follow if the recovery stalls — leaving the post-2026 margin algorithm dependent on volume.

Market Reaction

• Pre-print setup: DHR closed at $235.75 on January 27, up 3.0% year-to-date and near the top of its $174.64–$250.59 52-week range, having rallied ~7% off the post-Q3 reaction close (~$221). It entered the print on a run-up, with the S&P 500 +1.9% YTD.
• Reaction-day move: Shares gapped down −2.9% at the open ($229.00) and closed at $224.54, −4.8% (−$11.21) — the worst single-session reaction in our coverage window. The intraday low was $223.09 (−5.4%); the high barely reached the prior close.
• Volume: 7.8M shares versus a 3.3M 30-day average (2.4x), confirming genuine repositioning.
• Benchmark: The S&P 500 was flat (0.0%) on the session, so the entire −4.8% was stock-specific.

The sell-off is a sell-the-news de-rate of a run-up, not a verdict on the quarter. Three things drove it: the stock had rallied near its 52-week high into the print; the 2026 EPS guide of $8.35–$8.50 confirmed the high-single-digit framework already laid out in October rather than beating it; and the Q4 optics softened (core +2.5% decel, adjusted operating margin −130bp). What the day under-weighted is the substance — bioprocessing equipment returned to growth, the respiratory endemic was raised, China is moderating, and the M&A environment turned more constructive. The pullback to $224.54 reverses most of the run-up and improves the entry; the stock remains ~10% below its 52-week high with the equipment up-cycle just starting.

Street Perspective

Debate: Was the −4.8% Reaction a De-Rate or a Buying Opportunity?

Bull view: The reaction is mechanical — a run-up into the print plus an in-line (not below) guide. The fundamentals improved: equipment inflected, respiratory was raised, China is moderating, and M&A is loading. At $224.54 on a $8.42 guide midpoint (~26.7x), with conservative low-end-core construction and capital deployment excluded, the pullback is a gift on a compounder still below its historical multiple.

Bear view: The market is right to fade it. Core decelerated to +2.5%, margins fell 130bp, EPS growth slowed to +4%, and the 2026 guide skews to 3% core. At ~26.7x for high-single-digit EPS growth that depends on a back-half recovery and conservative assumptions that may simply be realistic, there is little margin of safety if the macro recovery stalls.

Our take: Bull. The de-rate is a run-up unwinding against a guide that confirmed rather than missed, and the fundamentals moved the right way on the metric that matters most (equipment). At ~26.7x for a best-in-class compounder with an inflecting equipment cycle, a raised respiratory base, conservative guidance, and excluded capital-deployment upside, the 12-month total-return setup beats the S&P. The pullback improves, rather than impairs, the case.

Debate: Is the Bioprocessing Equipment Turn Durable?

Bull view: Three consecutive quarters of sequential order growth plus a Q4 revenue inflection is a genuine turn, supported by years of deferred investment against rising biologic volumes and a reshoring tailwind that is "early innings." Management guides equipment flat, so the order momentum is pure upside. A durable equipment up-cycle pushes bioprocessing above high-single-digit and the 2026 core to the upper half of the range.

Bear view: One quarter of revenue growth off an easy comp does not make a trend — management itself won't call it. Orders remain below historical levels, the momentum is in shorter-cycle brownfield work (not the larger greenfield projects), and trade/policy uncertainty could stall conversion again. Flat is the right guide because the turn is unproven.

Our take: Lean bull, with management's caution noted. The order trajectory (three straight sequential increases) plus the structural deferred-demand and reshoring backdrop argue the turn is real, even if the slope is uncertain. The conservative flat guide means we are paid to wait — any durable equipment growth is incremental to the +7–9% EPS algorithm. This is the key swing factor for an upgrade in conviction through 2026.

Debate: Does Capital Deployment Become the 2026 Catalyst?

Bull view: Net leverage below 2x, ~$5.3B FCF, a "more constructive" M&A environment, and explicit readiness for something "more sizable" — all excluded from a guide that already clears +7–9% EPS growth. A well-priced, DBS-compoundable acquisition is Danaher's historical value-creation engine and would be a clear step-change catalyst.

Bear view: M&A is unscheduled and unpredictable; large-cap healthcare-tools assets carry integration and valuation risk; and a transformative deal could pressure the balance sheet or distract management while the core is still recovering. Buybacks help at the margin but are not transformative.

Our take: Bull. With the balance sheet primed and the environment constructive, capital deployment is the most likely source of upside to the multi-year algorithm in 2026. Danaher's M&A track record and discipline make the optionality genuinely valuable; an accretive deal would be the catalyst that re-rates the stock back toward its historical multiple.

Model & Valuation Framework

Valuation framework: At $224.54 post-print and the $8.42 midpoint of the 2026 guide, DHR trades at ~26.7x forward — below the middle of its historical 25–30x range for a compounder re-accelerating to high-single-digit EPS growth with an inflecting equipment cycle and excluded capital-deployment upside. Our base case applies ~29x to ~$8.55 of 2026 EPS (guide plus modest buyback) for a ~$248 fair value, ~10% above the post-print price, with the bull case (equipment up-cycle continuing, an accretive deal, and/or a faster Life Sciences recovery lifting EPS toward $9.00 at the upper multiple) supporting $270–290 — back above the prior 52-week high. The bear case (equipment stalls, Life Sciences lingers, multiple compresses to ~24x on the $8.35 low end) implies ~$200, ~11% downside. The risk/reward remains favorable for Outperform, with the equipment inflection and M&A optionality as the asymmetric upside.

Thesis Scorecard: Grading the Q3 Signposts

At the Q3 upgrade we set the conditions for maintaining Outperform. Q4/FY25 cleared most of them, including the key one (equipment).

Scorecard summary: Five signposts tripped bullish or better — including the most important (the equipment inflection) — and two were confirmed/in line (the 2026 guide met but did not beat the framework; capital deployment is loading but no deal has landed). Nothing tripped bearish.

Updated Thesis Scorecard Post-Earnings

Overall: Thesis strengthened. The central bull pillar (bioprocessing) reached its key milestone with the equipment turn; the capital-deployment pillar is loading toward action; and the 2026 algorithm was formally confirmed. The binding bear (narrow core growth) continues to ease, with Life Sciences finally positive and 2026 guided to accelerate.

Action: Maintain Outperform. The thesis was confirmed on every count that matters and the −4.8% pullback improves the risk/reward. Watch the equipment turn's durability and any M&A as the next legs of upside; the Q1 2026 print (April) and the pace of the back-half recovery are the next checkpoints.

Bottom Line: The Milestone Quarter the Tape Didn't Reward

Strip out the price action and Q4/FY2025 was a milestone quarter for the thesis. FY25 adjusted EPS landed at the $7.80 high end with $5.3B of free cash flow at 145% conversion — the 34th straight year above 100%. More importantly, the one leg of the bioprocessing recovery we had been waiting on since initiation finally turned: equipment returned to growth on a third consecutive quarter of sequential order growth. Management raised the respiratory endemic assumption to ~$1.8B, sized the 2026 China diagnostics drag down to ~$75–100M, and struck its most M&A-ready tone of our coverage window with the balance sheet primed.

The 2026 guide — 3–6% core and $8.35–$8.50 adjusted EPS (+7–9%) — confirmed the high-single-digit framework laid out in October without beating it, and that is the proximate reason the stock fell 4.8%. The construction is conservative: built off the low end of core, equipment assumed flat despite returning to growth, capital deployment excluded, and the only raised assumption (respiratory) being where the data forced it. Each of those choices is a potential source of upside rather than risk, and the 2025 pattern — raise as the year confirms — is the likely template for 2026.

The −4.8% reaction was a sell-the-news de-rate of a run-up into a near-52-week-high, not a verdict on the business. At $224.54 on the $8.42 guide midpoint (~26.7x), a best-in-class compounder with an inflecting equipment cycle, a raised respiratory base, a moderating China headwind, and excluded capital-deployment upside is set up to beat the S&P over the next twelve months, with the multiple still below its historical range. We are maintaining Outperform, with the durability of the equipment turn and any M&A as the asymmetric upside that could carry the stock back toward its prior highs.

What we are watching into Q1 2026 (April):